Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer

BACKGROUND: Antibody-drug conjugate (ADC) construction poses numerous challenges that limit clinical progress. In particular, common bioconjugation methods afford minimal control over the site of drug coupling to antibodies. Here, such difficulties are overcome through re-bridging of the inter-chain...

Descripción completa

Detalles Bibliográficos
Autores principales: Greene, Michelle K., Chen, Ting, Robinson, Eifion, Straubinger, Ninfa L., Minx, Charlene, Chan, Darren K. W., Wang, Jun, Burrows, James F., Van Schaeybroeck, Sandra, Baker, James R., Caddick, Stephen, Longley, Daniel B., Mager, Donald E., Straubinger, Robert M., Chudasama, Vijay, Scott, Christopher J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653048/
https://www.ncbi.nlm.nih.gov/pubmed/32913288
http://dx.doi.org/10.1038/s41416-020-01046-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653048/
https://www.ncbi.nlm.nih.gov/pubmed/32913288
http://dx.doi.org/10.1038/s41416-020-01046-6

Ejemplares similares